Twin City Private Wealth LLC Decreases Stake in Pfizer Inc. (NYSE:PFE)

Twin City Private Wealth LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 11.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 40,132 shares of the biopharmaceutical company’s stock after selling 5,160 shares during the period. Twin City Private Wealth LLC’s holdings in Pfizer were worth $1,065,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mountain Hill Investment Partners Corp. purchased a new position in Pfizer in the 4th quarter valued at $57,000. Crowley Wealth Management Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth $57,000. Vanguard Group Inc. increased its stake in shares of Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock worth $13,756,738,000 after acquiring an additional 2,285,276 shares during the last quarter. Paces Ferry Wealth Advisors LLC increased its stake in shares of Pfizer by 15.0% in the 4th quarter. Paces Ferry Wealth Advisors LLC now owns 9,317 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 1,217 shares during the last quarter. Finally, Samalin Investment Counsel LLC increased its stake in shares of Pfizer by 2.4% in the 4th quarter. Samalin Investment Counsel LLC now owns 25,418 shares of the biopharmaceutical company’s stock worth $674,000 after acquiring an additional 605 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $26.20 on Monday. The company has a market cap of $148.61 billion, a P/E ratio of 18.58, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a 50-day moving average of $26.17 and a two-hundred day moving average of $27.04. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on PFE shares. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.